Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H3J6
UPID:
MTRFR_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H3J6; Q8WUC6
Background:
The Mitochondrial Translation Release Factor in Rescue plays a crucial role in mitochondrial function by ensuring the accuracy of protein synthesis. It is part of a quality control pathway that responds to interruptions during elongation, working alongside MTRES1 to eject unfinished nascent chains and peptidyl transfer RNA from stalled ribosomes. This mechanism is vital for maintaining mitochondrial integrity and function.
Therapeutic significance:
Linked to diseases such as Combined oxidative phosphorylation deficiency 7 and Spastic paraplegia 55, autosomal recessive, understanding the role of this protein could open doors to potential therapeutic strategies. Its involvement in mitochondrial disease and neurodegenerative disorders highlights its potential as a target for therapeutic intervention.